Related Experiment Video
Updated: Jun 18, 2026

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
Current treatment options for retinal angiomatous proliferans (RAP)
Bhaskar Gupta1, Sreedhar Jyothi, Sobha Sivaprasad
1Ophthalmology Department, King's College Hospital, London, UK.
Abstract:
Retinal angiomatous proliferation (RAP) accounts for 12-15% of all patients with neovascular age-related macular degeneration (NV-AMD). However, this subtype is often excluded from clinical trials aimed at assessing the efficacy of various treatment options for NV-AMD. Thus, there are no established protocols for the management of RAP. This review of current literature on RAP compares the outcomes of various treatment options for this condition and highlights the lack of clinical trials and paucity of long-term data on this relatively common condition.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Diabetic Retinopathy